[go: up one dir, main page]

CR10356A - Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3 - Google Patents

Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3

Info

Publication number
CR10356A
CR10356A CR10356A CR10356A CR10356A CR 10356 A CR10356 A CR 10356A CR 10356 A CR10356 A CR 10356A CR 10356 A CR10356 A CR 10356A CR 10356 A CR10356 A CR 10356A
Authority
CR
Costa Rica
Prior art keywords
benzilphthalazinona
derivatives
substituted
histamine antagonists
histamine
Prior art date
Application number
CR10356A
Other languages
English (en)
Inventor
Martin Gore Paul
Paul Hancock Ashley
Teanby Hodgson Simon
Jane Kindon Leanda
Alexandrou Procopiou Panayiotis
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0607839A external-priority patent/GB0607839D0/en
Priority claimed from GB0706160A external-priority patent/GB0706160D0/en
Priority claimed from GB0706176A external-priority patent/GB0706176D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CR10356A publication Critical patent/CR10356A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invencion se refiere a compuestos de formula (I), y a sales de los mismos, a procedimientos para su preparacion, a composiciones que los contienen y a su uso en el tratamiento de diversas enfermedades tales como rinitis alergica.
CR10356A 2006-04-20 2008-10-07 Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3 CR10356A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0607839A GB0607839D0 (en) 2006-04-20 2006-04-20 Compounds
GB0706160A GB0706160D0 (en) 2007-03-29 2007-03-29 Compounds
GB0706176A GB0706176D0 (en) 2007-03-29 2007-03-29 Compounds

Publications (1)

Publication Number Publication Date
CR10356A true CR10356A (es) 2008-11-26

Family

ID=38226516

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10356A CR10356A (es) 2006-04-20 2008-10-07 Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3

Country Status (19)

Country Link
US (2) US20080039444A1 (es)
EP (1) EP2007735B1 (es)
JP (1) JP4489143B2 (es)
KR (1) KR20090007604A (es)
AR (1) AR060535A1 (es)
AT (1) ATE486063T1 (es)
AU (1) AU2007242842A1 (es)
BR (1) BRPI0710156A2 (es)
CA (1) CA2649029A1 (es)
CO (1) CO6140030A2 (es)
CR (1) CR10356A (es)
DE (1) DE602007010118D1 (es)
EA (1) EA200801996A1 (es)
MA (1) MA30405B1 (es)
MX (1) MX2008013406A (es)
NO (1) NO20084363L (es)
PE (1) PE20080360A1 (es)
TW (1) TW200811116A (es)
WO (1) WO2007122156A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200730498A (en) 2005-12-20 2007-08-16 Glaxo Group Ltd Compounds
ATE459358T1 (de) * 2006-12-20 2010-03-15 Glaxo Group Ltd 4-benzyl-1(2h)-phthalazinone als h1-rezeptor- antagonisten
CL2008003036A1 (es) * 2007-10-16 2009-05-08 Glaxo Group Ltd Composicion farmaceutica acuosa que comprende 4-[(4-clorofenil)metil]-2-({(2r)-1-[4-(4-{[3-(hexahidro-1h-azepin-1-il)propil]oxi}fenil)butil]-2-pirrolidinil}metil)-1(2h)-ftalazinona; envase que la comprende; y uso para el tratamiento de enfermedades inflamatorias y/o alergicas tal como rinitis alergica.
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤
GB0811447D0 (en) * 2008-06-20 2008-07-30 Glaxo Group Ltd Formulations
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
US20120157446A1 (en) * 2009-06-29 2012-06-21 Glaxo Group Limited Medical use
CA2798007C (en) 2010-05-19 2018-10-23 Sandoz Ag Preparation of posaconazole intermediates
AU2011254656B2 (en) 2010-05-19 2015-04-16 Sandoz Ag Process for the preparation of chiral hydrazides
BR112012029228A2 (pt) * 2010-05-19 2021-08-03 Sandoz Ag processo para a preparação de um sal de cloreto de hidrogênio, sal de cloreto de hidrogênio, sal de cloreto de hidrogênio cristalino, uso de um sal e uso do processo
WO2012045729A1 (en) 2010-10-05 2012-04-12 Glaxo Group Limited Imidazo [1, 2 -a] pyridine and pyrazolo [1, 5 -a] pyridine derivatives as trpv1 antagonists
WO2012072512A1 (en) 2010-11-29 2012-06-07 Glaxo Group Limited N-cyclobutyl-imidazopyridine or -pyrazolopyridine carboxamides as trpv1 antagonists
US8754101B2 (en) 2011-04-11 2014-06-17 Glaxo Group Limited N-cyclobutyl-imidazopyridine-methylamine as TRPV1 antagonists
CN108329303A (zh) 2011-06-16 2018-07-27 桑多斯股份公司 制备手性化合物的方法
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
MX2016014859A (es) 2014-05-12 2017-06-27 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmaceuticas que comprenden danirixina para tratar enfermedades infecciosas.
BR112022019245A2 (pt) 2020-03-26 2022-11-16 Glaxosmithkline Ip Dev Ltd Inibidores de catepsina para prevenir ou tratar infecções virais
WO2022251497A1 (en) * 2021-05-27 2022-12-01 Schrödinger, Inc. Heterocyclic compounds and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH572914A5 (es) * 1971-01-22 1976-02-27 Asta Werke Ag Chem Fab
US3813384A (en) * 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
ATE49205T1 (de) * 1984-09-14 1990-01-15 Asta Pharma Ag Substituierte benzylphthalazinon-derivate.
ES2031813T3 (es) * 1985-11-11 1993-01-01 Asta Pharma Ag Procedimiento para la preparacion de derivados de 4-bencil-1-(2h)-ftalazinona.
EP0289939A1 (de) * 1987-05-08 1988-11-09 ASTA Pharma AG Neue 4-Benzyl-1-(2H)-phthalazinon-Derivate mit einem Aminosäurerest
CZ199593A3 (en) * 1992-10-02 1994-04-13 Asta Medica Ag Phthalazinone derivatives exhibiting anti-arrhythmic and analgesic activity and eliminating resistance to a plurality of medicaments (mdr)
US6180629B1 (en) * 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
ES2209337T3 (es) * 1998-08-14 2004-06-16 Pfizer Inc. Agentes antitromboticos.
GB0224084D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
AU2004222336B2 (en) * 2003-03-18 2010-06-03 Merck Sharp & Dohme Corp. Amino cyclobutylamide modulators of chemokine receptor activity
JP4735261B2 (ja) * 2003-06-27 2011-07-27 Ｍｓｄ株式会社 ヘテロアリールオキシ含窒素飽和ヘテロ環誘導体

Also Published As

Publication number Publication date
BRPI0710156A2 (pt) 2012-06-05
US20090105225A1 (en) 2009-04-23
ATE486063T1 (de) 2010-11-15
AR060535A1 (es) 2008-06-25
WO2007122156A9 (en) 2008-01-24
CO6140030A2 (es) 2010-03-19
JP4489143B2 (ja) 2010-06-23
KR20090007604A (ko) 2009-01-19
PE20080360A1 (es) 2008-05-22
WO2007122156A1 (en) 2007-11-01
MA30405B1 (fr) 2009-05-04
MX2008013406A (es) 2008-11-04
CA2649029A1 (en) 2007-11-01
EP2007735A1 (en) 2008-12-31
DE602007010118D1 (de) 2010-12-09
EP2007735B1 (en) 2010-10-27
EA200801996A1 (ru) 2009-04-28
TW200811116A (en) 2008-03-01
US20080039444A1 (en) 2008-02-14
NO20084363L (no) 2008-11-17
AU2007242842A1 (en) 2007-11-01
JP2009534351A (ja) 2009-09-24

Similar Documents

Publication Publication Date Title
CR10356A (es) Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3
CR20170367A (es) Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
ECSP099750A (es) Imidazoquinolinas con propiedades inmunomoduladoras
GT201400031A (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
UY32379A (es) Derivados de n-heteroarilo sulfonammida sustituidos, sales, solvatos o tautómero farmacéuticamente aceptables, procesos de preparación, intermedios, composicones conteniéndolos y aplicaciones.
UY32848A (es) Compuestos heterocíclicos de oxima
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
GT200800242A (es) Derivados biciclicos como inhibidores de cetp
SV2011003802A (es) Derivados de triazol utiles para el tratamiento de enfermedades
UY31166A1 (es) Nuevos indazoles sustituidos, su preparación y su utilización en terapeutica
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
CO6321276A2 (es) Derivados de tiazol usados como inhibidores de pi3- cinasa
UY32648A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades
NI201200061A (es) Derivados de quinazolina-4(3h)-ona utilizados como inhibidores de la cinasa de pi3
UY31922A (es) Compuestos
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
CU20100111A7 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
UY32055A (es) Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones.
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
CR11665A (es) Farmacoforos duales-antagonistas muscarinicos de pde4
UY30424A1 (es) Derivados de quinolina, su preparacion, su uso y medicamentos que comprenden los mismos.
UY30729A1 (es) Derivados de pirrol, su preparacion y su utilizacion en terapéutica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)